Literature DB >> 2752561

Peripheral vascular disease. Rheologic variables during controlled ischemia.

G Ciuffetti1, M Mercuri, E Mannarino, M K Robinson, S E Lennie, G Lowe.   

Abstract

The quantitative and qualitative behavior of hemorheologic factors both at rest and after treadmill exercise in 30 male patients with stage II peripheral vascular disease compared with 20 sex- and age-matched healthy controls have been studied. The aim of our study was to identify functional rheologic markers for peripheral vascular disease. At rest, whole blood viscosity (corrected for hematocrit at both high and low shear rates), fibrinogen levels (4.23 +/- 1.39 vs. 3.23 +/- 1.5), and white blood cell count (7.05 +/- 1.25 vs. 6.03 +/- 1.28) were significantly different between patients and controls. After treadmill exercise, white blood cell counts increased in both patients and controls, whereas only the filterability of mononuclear leukocytes showed a significant variation in the patient group (5.47 +/- 1.54 vs. 7.26 +/- 2.00, p less than 0.002). In this group, mononuclear filterability improved during the recovery period. The results suggest a relation between exercise-induced ischemia of the lower limb and mononuclear filterability in patients with peripheral vascular disease. Mononuclear filterability could be a functional rheologic marker for peripheral vascular disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752561     DOI: 10.1161/01.cir.80.2.348

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  2 in total

1.  Do leukocytes have a role in the cerebral no-reflow phenomenon?

Authors:  M Mercuri; G Ciuffetti; R Lombardini; C Neri; M Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

2.  Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

Authors:  G Ciuffetti; M Mercuri; C Ott; R Lombardini; R Paltriccia; G Lupattelli; L Santambrogio; E Mannarino
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.